This clinical trial is focused on studying a condition called Myelofibrosis, which is a type of blood cancer that affects the bone marrow. The study is comparing a new treatment called Imetelstat with the best available therapies currently used for patients with intermediate-2 or high-risk myelofibrosis who have not responded to a type of medication known as a JAK-inhibitor. Imetelstat is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to compare the overall survival of patients treated with Imetelstat versus those receiving the best available therapy. Participants in the study will be randomly assigned to receive either Imetelstat or one of the standard treatments, which may include medications like Danazol, Corticosteroids, Busulfan, Anagrelide, Cladribine, Hydroxycarbamide, Mercaptopurine, or other supportive care options. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and response to the treatment. The main goal is to see if Imetelstat can help patients live longer compared to the current best available therapies. Participants will be closely monitored for any changes in their condition, including symptoms and spleen size, which is often affected in myelofibrosis. The study aims to provide valuable information that could lead to better treatment options for people with this challenging condition.